Hybrid Thoracoscopic Surgical and Transvenous Catheter Ablation of Atrial Fibrillation  by Pison, Laurent et al.
b
r
b
t
Journal of the American College of Cardiology Vol. 60, No. 1, 2012
© 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00Heart Rhythm Disorders
Hybrid Thoracoscopic Surgical and
Transvenous Catheter Ablation of Atrial Fibrillation
Laurent Pison, MD,* Mark La Meir, MD,† Jurren van Opstal, MD, PHD,* Yuri Blaauw, MD, PHD,*
Jos Maessen, MD, PHD,† Harry J. Crijns, MD, PHD*
Maastricht, the Netherlands
Objectives The purpose of this study was to evaluate the feasibility, safety, and clinical outcomes up to 1 year in patients under-
going combined simultaneous thoracoscopic surgical and transvenous catheter atrial fibrillation (AF) ablation.
Background The combination of the transvenous endocardial approach with the thoracoscopic epicardial approach in a single
AF ablation procedure overcomes the limitations of both techniques and should result in better outcomes.
Methods A cohort of 26 consecutive patients with AF who underwent hybrid thoracoscopic surgical and transvenous cath-
eter ablation were followed, with follow-up of up to 1 year.
Results Twenty-six patients (42% with persistent AF) underwent successful hybrid procedures. There were no complica-
tions. The mean follow-up period was 470  154 days. In 23% of the patients, the epicardial lesions were not
transmural, and endocardial touch-up was necessary. One-year success, defined according to the Heart Rhythm
Society, European Heart Rhythm Association, and European Cardiac Arrhythmia Society consensus statement for the
catheter and surgical ablation of AF, was 93% for patients with paroxysmal AF and 90% for patients with persistent
AF. Two patients underwent catheter ablation for recurrent AF or left atrial flutter after the hybrid procedure.
Conclusions A combined transvenous endocardial and thoracoscopic epicardial ablation procedure for AF is feasible and safe,
with a single-procedure success rate of 83% at 1 year. (J Am Coll Cardiol 2012;60:54–61) © 2012 by the American
College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2011.12.055e
s
lIn paroxysmal atrial fibrillation (AF), success rates of catheter
ablation (CA) exceed 80%, and recurrence is associated mostly
with pulmonary vein (PV) reconnection (1,2). By combining
PV isolation, complex and fractionated atrial electrographic
ablation, and linear lesions in patients with persistent AF,
success rates without antiarrhythmic drugs (AADs) surpass
70% (3,4). However, multiple procedures are often necessary,
and creating linear lesions is sometimes challenging.
Surgical AF ablation has evolved from the original Cox
maze procedure toward a minimally invasive, video-assisted
procedure with new ablation tools to isolate the PVs and create
linear lesions without opening the heart (5). Nevertheless, even
ipolar radiofrequency (RF) energy cannot guarantee transmu-
al lesions (6). Linear lesions such as the mitral isthmus cannot
e created solely from the epicardium, and proving bidirec-
ional block epicardially can be challenging (7).
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We report our initial experience with long-term follow-up
of minimally invasive epicardial bilateral PV isolation and
linear lesions in combination with endocardial proof of con-
duction block and endocardial touch-up if indicated.
Methods
Patient selection. Twenty-six consecutive patients with
symptomatic AF underwent hybrid thoracoscopic surgical
and transvenous CA with follow-up of 1 year. Definitions of
paroxysmal, persistent, and longstanding persistent AF,
success and failure of ablation, and follow-up monitoring
were based on the Heart Rhythm Society, European Heart
Rhythm Association, and European Cardiac Arrhythmia
Society consensus statement (3). Therapy with at least 1
AAD had failed. Other selection criteria were previously
failed CA, left atrial volume 29 ml/m2, persistent or
ongstanding persistent AF, or patient preference for a
ybrid procedure instead of a percutaneous approach.
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July 3, 2012:54–61 Hybrid Surgical and Catheter AF AblationEleven patients (44%) had prior CA for AF or atrial flutter
(AFL). All patients underwent transthoracic echocardiog-
raphy, cardiac computed tomography, and pulmonary func-
tion testing preoperatively.
Hybrid procedure. The procedure was performed under gen-
eral anesthesia with double-lumen endotracheal tube placement
for selective lung ventilation. Transesophageal echocardiogra-
phy was used to exclude a thrombus in the left atrium (LA).
On the right side, a 12-mm camera port was placed in the
fifth intercostal space midaxillary line and in the sixth or
seventh intercostal space anterior axillary line. A 5-mm
working port was placed in the third intercostal space
anterior axillary line. The pericardium was opened anterior
to the phrenic nerve. Blunt dissection was used to open the
transverse and oblique sinuses.
Via the femoral venous approach, a His bundle (St. Jude
Medical, St. Paul, Minnesota) and coronary sinus catheter
(Medtronic, Minneapolis, Minnesota) were placed under
fluoroscopy, and transseptal puncture was performed with a
long 8-F sheath (SL0, St. Jude Medical) into the LA. The
patient then underwent heparinization (1,000 U heparin per
10 kg body weight and a heparin infusion), with activated
clotting time 300 s. During rapid ventricular pacing, we
njected contrast through the long sheath to visualize left
trial anatomy. The PVs were mapped with a circular
apping catheter (Lasso, Biosense Webster, Diamond Bar,
alifornia). Antral isolation of the right PVs as a pair was
erformed with 4 to 6 applications using a bipolar RF clamp
Atricure, West Chester, Ohio) (Fig. 1). Each application
ad a duration of about 15 s, with a median output of 10 to
5 W. The same port incisions were made on the left side
ut placed more posteriorly (Fig. 2). The pericardium was
ivided posterior to the phrenic nerve. Left PV isolation was
onducted as described earlier. We did not attempt ablation
f the ganglionated plexi.
In patients with severe chronic obstructive pulmonary
isease , we performed thoracoscopic epicardial isolation of
he PVs only on the right, and the left PVs were isolated
sing a cryothermal energy balloon catheter (Arctic Front,
ryocath, Montreal, Quebec City, Canada) endocardially to
void bilateral sequential lung deflation.
The end point for PV ablation was entrance and exit
lock. We defined exit block as local capture in the PV
uring pacing from the Lasso catheter (output 10 mA, pulse
idth 2 ms) without conduction to the LA. In the case of
inus rhythm after PV isolation, reinduction of AF was
ttempted 5 times by pacing in the coronary sinus for 10
econds at the shortest cycle length resulting in 1:1 atrial
apture. AF was considered inducible if it lasted more than 1
min. If AF became noninducible, isoproterenol was infused at
rates of 10 to 30 g/min. If AF had not terminated or still was
inducible, linear lesions were deployed.
A roof line (connecting both superior PVs) and an
inferior line (connecting both inferior PVs) were made
epicardially using a bipolar RF pen or linear pen device
(Isolater Pen and Coolrail, Atricure). If the right atrium wasdilated, 2 additional ablation
lines were placed: 1 encircling
the superior caval vein using the
clamp, the other connecting both
caval veins using the pen.
By making a roof and an infe-
rior line, we isolated the posterior
LA (box lesion). If entrance and
exit block were not reached, we
identified the conduction gaps en-
docardially and ablated those with
a 3.5-mm-tip catheter (Thermo-
Cool, Biosense Webster). The lo-
cation of the linear lesions was
visualized with the linear pen de-
vice in situ and using fluoroscopy.
A left isthmus line was made
in 3 patients using the bipolar RF pen device. The line was
started from the ablation line on the antrum of the left
inferior PV toward and crossing the coronary sinus. All
patients needed endocardial touch-up ablation to reach
bidirectional block, starting from the mitral annulus toward
or inside the coronary sinus. If the patient was known to
have typical AFL or if this arrhythmia occurred during the
procedure, the cavotricuspid isthmus (CTI) was ablated
endocardially. The endpoint was bidirectional block. In 7
patients, the left atrial appendage was removed using a
stapling device.
The pericardium was approximated with a stitch, and a
chest tube was placed in both pleural cavities. There was no
drain left in the pericardial space.
Figure 1 Right Pulmonary Vein Isolation
A large antral lesion (arrow) is created using a bipolar radiofrequency clamp,
resulting in complete isolation of the right pulmonary veins (PVs). The antrum
of the right PVs (*) is clearly visible. RL  right lung.
Abbreviations
and Acronyms
AAD  antiarrhythmic drug
AF  atrial fibrillation
AFL  atrial flutter
AT  atrial tachycardia
CA  catheter ablation
CTI  cavotricuspid
isthmus
LA  left atrium
PV  pulmonary vein
RF  radiofrequency
SVT  supraventricular
tachycardia
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Hybrid Surgical and Catheter AF Ablation July 3, 2012:54–61Low-molecular-weight heparin was started 6 h after the
procedure, and on the second post-operative day, acenocou-
marol was reinitiated.
Patients restarted as soon as possible their pre-operative
AAD regimens. Acenocoumarol and AADs were discon-
tinued after the 6-month monitoring visit confirmed the
absence of atrial arrhythmia.
Long-term follow-up. Any symptomatic patient not in
sinus rhythm was cardioverted before the 3-month follow-up
visit. One patient had a pacemaker, which was used for
monitoring. The remaining patients underwent 7-day contin-
uous Holter monitoring at 3, 6, 9, and 12 months. If 7-day
Holter monitoring was not available, patients underwent at
least 24-h Holter monitoring. According to current guidelines,
success was defined as no episode of AF, AFL, or any atrial
tachycardia (AT) lasting more than 30 s off AAD after the
3-month blanking period.
Statistical analysis. Data were retrospectively entered into
a database. Statistical analysis was performed using SPSS
version 16.0 (SPSS, Inc., Chicago, Illinois). Continuous
variables are summarized with means and standard devia-
tions. Outcomes are displayed using Kaplan-Meier plots
and were compared using log-rank tests. Any episode of
AF, AFL, or AT lasting more than 30 seconds detected
after the 3-month post-procedural period by electrocardi-
ography, pacemaker interrogation, or 7-day, 48-h, or 24-h
continuous Holter monitoring performed at 6, 9, and 12
months was considered failure.
Results
Perioperative results. Twenty-six patients underwent hy-
brid procedures between May 29, 2008, and February 25,
2010. Patients’ baseline characteristics are shown in Table 1.
Ten patients had persistent AF, and 1 had longstanding
persistent AF. Eleven patients had 1 or 2 (Patient #25)
previous CAs. None of the PVs were isolated in those
Figure 2 Placement of Ports on the Left Side of the Patientpatients, and there were no epicardial scars indicative of ptransmural lesions. The mean follow-up period was 470 
54 days (range: 221 to 858 days). The mean length of
ospital stay was 7 2 days (range: 5 to 13 days), and mean
ntensive care unit stay for post-procedural recovery was
.0  0.2 days (range: 1 to 2 days). The median length of
he hybrid procedure (from initial skin incision to skin
losure) was 280  84 min (range: 195 to 505 min).
Eleven patients were in AF at the start of the procedure.
n all patients, we achieved bidirectional block of all the PVs
Fig. 3). In 2 patients, we did not perform any other lesion,
ecause AF was not inducible. In 1 patient with inducible
F after PV isolation, we performed an additional roof line
nly. In 1 patient with inducible right AFL after PV
solation, we performed an additional CTI line only. There-
fter, no arrhythmia could be induced. In 22 patients, we
reated box lesions epicardially. In 17 patients (77%), we
ere able to demonstrate endocardial entrance and exit
lock in the box during sinus rhythm. After endocardial
ouch-up in 5 patients (23%), we completed the box lesions.
n 3 patients, there was a gap at the junction of the right
uperior PV with the roof of the LA. One patient had a gap
n the lateral portion of the roof line, and 1 patient in the
iddle of the inferior line. Because of ongoing AF or
rganization into mitral isthmus–dependent AFL, we per-
ormed in 3 patients mitral isthmus lines epicardially. In all
ases, the lines had to be completed from the endocardium
r coronary sinus, with a mean of 1.6  0.5 applications of
F energy, resulting in bidirectional block (Fig. 4). In 2
atients, CTI ablation was performed. One patient needed
lectrical cardioversion at the end of the procedure because
f ongoing AF. All other patients were in sinus rhythm.
wenty-four patients (92%) were discharged on their pre-
perative AAD regimens (amiodarone in 6 of 24 [25%]).
ll patients were discharged on acenocoumarol.
ollow-up. Twenty-four patients (92%) reached 1-year
ollow-up, and 96% underwent 7-day Holter monitoring 1
ear after the procedure. The remaining 2 patients (8%)
eached 6-month follow-up, and there was 100% compli-
nce with 7-day Holter monitoring (Table 2).
At 1 year, 22 of 24 patients (92%) were in sinus rhythm,
ith no episodes of AF, AFL, or AT lasting longer than 30 s
n office follow-up, Holter monitoring, or pacemaker interro-
ation (Fig. 5). None of those patients were on AADs, and 5
21%) were on acenocoumarol. One-year success, defined
ccording to the Heart Rhythm Society, European Heart
hythm Association, and European Cardiac Arrhythmia So-
iety consensus statement (freedom from AF, AFL, and AT
ff AADs), was 93% for patients with paroxysmal AF and 90%
or patients with persistent AF. Two of those 22 patients (9%)
nderwent CA for recurrent AF or left AFL after the hybrid
rocedure (Table 3). There was no statistically significant differ-
nce in patients with or without previous CA regarding the
resence of sinus rhythm after 1 year without AADs (p 1.00).
This means a single-procedure success rate (sinus rhythm
ithout AAD and/or redo procedure) of 79% at 1 year for
aroxysmal AF (11 of 14 patients) and 90% for persistent
Baseline CharacteristicsTable 1 Baseline Characteristics
Patient #
Age
(yrs) Sex
EF
(%) AF Type
AF Duration
(months)
LA Volume (ml)/
lpsa (mm)
BMI
(kg/m2)
Previous
CA Hypertension CAD
CHADS2
Score COPD Lesion Set Follow-Up
1 70 M 63 Pers 12 133/51 24.2 No Yes Yes 1 No PVI, box, mitral
isthmus line
1 yr: NSR without AADs
2 54 M 66 Pers 60 110/47 26.3 No Yes No 1 No PVI, box, bicaval
line, CTI
2 yrs: NSR without AADs
3 62 M 53 Pers 24 97/53 28.8 Yes No Yes 0 No PVI, box 1 yr: NSR without AADs
4 69 M 44 Pers 72 96/46 31 Yes No Yes 0 No PVI, box, bicaval
line, SCV
6 months: NSR with
sotalol
5 52 M 43 Pers 36 95/46 24.5 No No No 1 No PVI, box, bicaval line,
SCV, ICV
1 yr: NSR without AADs
6 53 F 63 Pers 156 88/42 27.7 Yes No Yes 0 No PVI 1 yr: AF with flecainide
7 50 M 57 Pers 84 86/44 28.3 Yes No No 0 No PVI, box, bicaval line,
SCV, ICV
1 yr: NSR without AADs
8 48 F 49 Pers 36 83/40 22.9 No No No 0 No PVI, box, mitral
isthmus line
2 yrs: NSR without AADs
9 54 F 47 Pers 12 80/48 29.7 No No No 0 No PVI, box, bicaval line,
SCV, ICV
1 yr: NSR without AADs
10 60 M 55 Pers 12 71/36 22.1 No No No 0 No PVI, box 1 yr: NSR without AADs
11 46 M 56 Pers 48 38/32 24.3 Yes Yes No 1 Yes PVI, box, bicaval
line, SCV
1 yr: NSR without AADs
12 58 M 67 Parox 36 130/45 28.7 Yes Yes Yes 1 No PVI, box 1 yr: NSR after redo CA
LA flutter
13 70 M 63 Parox 36 111/42 23.8 No Yes Yes 1 No PVI, box 1 yr: NSR without AADs
14 62 F 61 Parox 36 110/45 26.2 No No Yes 0 No PVI, box 1 yr: NSR without AADs
15 57 M 62 Parox 24 99/45 30.9 No Yes No 1 No PVI, box 1 yr: AF with sotalol
16 60 M 62 Parox 108 90/48 28.1 No Yes Yes 1 Yes PVI, box 1 yr: NSR without AADs
17 66 M 57 Parox 120 84/45 23.5 No Yes Yes 1 Yes PVI, box 1 yr: NSR after redo CA
right PVs and roof line
18 62 M 67 Parox 156 84/46 26.9 No Yes No 1 No PVI 1 yr: NSR without AADs
19 66 M 63 Parox 108 82/44 32.2 Yes Yes No 1 No PVI, CTI line 1 yr: NSR without AADs
20 48 M 63 Parox 120 94/43 31.6 Yes No No 0 No PVI, box 1 yr: NSR without AADs
21 59 M 70 Parox 120 80/45 26.1 No Yes Yes 1 Yes PVI, box 1 yr: NSR without AADs
22 62 F 66 Parox 72 76/49 35.6 No Yes Yes 1 Yes PVI, box, mitral
isthmus line,
bicaval line, SCV
1 yr: NSR without AADs
23 63 F 65 Parox 92 70/36 19.7 Yes No No 0 No PVI, box,
bicaval line
2 yrs: NSR without AADs
24 38 F 60 Parox 36 59/32 23.5 Yes No No 0 No PVI, box, CTI 6 months: NSR without
AADs
25 47 M 60 Parox 72 51/36 26.2 Yes No No 1 No PVI, roof line 1 yr: NSR without AADs
26 42 F 60 Parox 60 48/35 23.7 No No No 0 No PVI, box, bicaval
line, SCV
1 yr: NSR without AADs
Baseline characteristics of all included patients with lesion set and follow-up results. No patient had previous cardiothoracic surgery or a cerebrovascular accident.
AAD  antiarrhythmic drug; AF  atrial fibrillation; BMI  body mass index; CA  catheter ablation; CAD  coronary artery disease; COPD  chronic obstructive pulmonary disease; CTI  cavotricuspid isthmus; EF  ejection fraction; ICV  inferior caval vein; LA  left
atrial; lpsa  left parasternal axis; NSR  normal sinus rhythm; Parox  paroxysmal; Pers  persistent; PVI  pulmonary vein isolation; SCV  superior caval vein.
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Hybrid Surgical and Catheter AF Ablation July 3, 2012:54–61AF (9 of 10 patients) and an overall single-procedure
success rate of 83% at 1 year.
At 6 months, 2 of 2 patients (100%) were in sinus rhythm, with
no episodes of AF, AFL, or AT lasting longer than 30 s. One of
these patients was taking flecainide, and they were both on
acenocoumarol. None of those patients had an additional CA
procedure.
The management of patients with recurrent supraventric-
ular tachycardia (SVT) after the 3-month blanking period is
summarized in Table 3. Four of 26 patients (15%) had SVT
recurrence, with a mean of 99  94 (range: 29 to 239)
SVT-free days after the blanking period. Two of these 4
patients underwent electrophysiologic studies and CA. One
patient was found to have AF due to a gap at the junction
Figure 3 Flow Diagram of the Stepwise Lesion Sets
See text for details. AF  atrial fibrillation; CTI  cavotricuspid isthmus; LA  leftof the right superior PV with the roof of the LA. The otherpatient had left AFL. These 2 patients were followed for at
least 5 months and did not experience further SVT off
AADs. The remaining 2 patients with SVT recurrence were
treated with AADs for paroxysmal AF.
Complications. No deaths or conversion to cardiopulmonary
bypass were encountered. No patient demonstrated paralysis of
the phrenic nerve. One patient had a pleural effusion drained 3
weeks after surgery. One patient stayed hospitalized for 13 days
because of difficulty controlling chest pain at the insertion sites of
the working ports, without signs of infection.
Discussion
Main findings. This report describes for the first time com-
NSR  normal sinus rhythm; PVI  pulmonary vein isolation; RA  right atrium.atrium;bined simultaneous thoracoscopic surgical and transvenous CA
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July 3, 2012:54–61 Hybrid Surgical and Catheter AF Ablationof paroxysmal and persistent AF. These 2 complementary
techniques performed in combination bear the potential of
treating AF with a single ablation procedure. According to
accepted definitions, our overall 1-year freedom from arrhyth-
mia without AADs was 92%, with only 2 patients needing
second CA procedures (3). Of note, almost half of the patients
with persistent AF and over a third of all patients had 1 or
more previous CA. The robustness of the hybrid approach lies
in its complementary nature, as represented by the fact that in
almost a quarter of patients, CA was needed to finish incom-
plete epicardial surgical lesions by endocardial touch-up, and
additional lesions such as the mitral isthmus line can be
performed rather quickly.
Hybrid procedure versus percutaneous CA techniques.
Jaïs et al. (8) found that if AF was inducible after PV
isolation in patients with paroxysmal AF, the addition of
linear lesions, with the end point of noninducibility, resulted
in 91% of patients free from arrhythmia without AADs
during a follow-up period of 18  4 months. To reach that
number, however, 31% of patients needed second proce-
dures. Using the same end point, our success rate off AADs
was comparable, but only 9% of patients needed second
procedures.
The single-procedure, drug-free success rate of the step-
Figure 4 Linear Lesion at the Mitral Isthmus
Two instruments placed epicardially visualize the location of this linear lesion
(asterisk indicates left inferior pulmonary vein, triangle indicates coronary
sinus). Bidirectional block across the mitral isthmus was determined using the
following criteria: 1) widely separated double potentials along the whole linear
lesion (double-headed arrow); 2) pacing lateral to the line, resulting in a proxi-
mal-to-distal activation sequence in the coronary sinus; 3) pacing immediately
septal from this linear lesion with the coronary sinus catheter (square), result-
ing in late activation (170 to 190 ms) on the ablation catheter (dagger) at the
lateral side of this line; and 4) the conduction time from the septal side of the
linear lesion to the lateral side gets shorter as the septal pacing site is moved
farther from the line. Double dagger indicates His catheter; thick arrow indi-
cates transesophageal echocardiographic probe.wise ablation approach for persistent AF as described byHaïssaguerre et al. (9) was 62% at 11 6 months. Allowing
for repeat procedures and the use of AADs, the 1-year
success rate increased to 95%. In our series, we followed a
comparable ablation strategy, and the single-procedure,
drug-free success rate at 1 year was 83%. Allowing for redo
procedures, this number increased to 92%.
The hybrid approach appears to result in better end-
points regarding rhythm control, for both paroxysmal and
persistent AF, using the same end points and ablation
strategy as described in other trials.
Approximately 80% of patients have at least partial recovery
of PV conduction at 4 months after PV isolation with unipolar
RF energy (10). Bipolar RF energy, as used in our series,
overcomes the heat sink by clamping the tissue and excluding
the effect of the circulating blood on ablation, which seems to
result in more persistent lesions (11). But even for such devices,
epicardial fat can prevent transmurality. In our series, box
lesions were incomplete after epicardial ablation alone in 23%
of the patients, and endocardial touch-up with unipolar RF
energy was necessary to achieve bidirectional block. The
possibility to perform such endocardial touch-up is 1 of the
major advantages of this procedure.
Hybrid procedure versus surgical ablation techniques.
By replacing the incisions of the traditional Cox maze III
procedure with less invasive linear lesions of ablation using
bipolar RF, Shen et al. (12) introduced the Cox maze IV
procedure. This approach still requires cardiopulmonary
bypass and at least 1 small right thoracotomy. Freedom
from AF recurrence was 91% at 12 months, with 67% of
patients off AADs. These figures are comparable with our
results, although in the case of the hybrid procedure, neither
cardiopulmonary bypass nor a thoracotomy is needed. None
of the existing surgical ablation technologies (even bipolar
RF energy) can guarantee complete transmurality. We
solved this issue by applying RF energy endocardially in the
case of incomplete lesions. Another shortcoming of the
surgical approach is the inability to precisely locate AF
triggers and to map AT or re-entry arrhythmias known to
occur during AF ablation (13). In the setting of a hybrid
procedure, however, it is possible to perform extensive
mapping to tailor the lesion set. Finally, during an epicardial
surgical AF ablation on the beating heart, it is technically
not possible to create a linear lesion across the CTI. In our
series, this was safely performed endocardially in 3 patients.
Hybrid procedure versus surgical ablation with epicardial
mapping. In 2009, Lockwood et al. (7) described tech-
niques for assessing conduction block across surgical lesions
on the basis of epicardial mapping. Using combinations of a
focal and bipolar RF device, as in our series, they achieved
complete block across linear lesions by the first set of RF
applications in only 21%. Several factors, such as epicardial
fat and local myocardial thickness, limit the depth of
penetration of RF energy and thus the creation of transmu-
ral lesions (14). After localization of the gaps, epicardial
ablation was repeated until complete bidirectional block
across all the linear lesions was achieved.
AAD use and type and results of monitoring in all included patients. The duration of AAD intake after the hybrid pro
NA  not available; PAF  paroxysmal atrial fibrillation; PM  pacemaker; other abbreviations as in T
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Hybrid Surgical and Catheter AF Ablation July 3, 2012:54–61In our series, pacing maneuvers and mapping techniques
were performed from the endocardial side. In 23% of our
patients, we were not able to create complete box lesions,
even after repeating epicardial ablation. To create com-
pletely transmural lesions, we applied unipolar RF energy
endocardially at the remaining gaps.
Krul et al. (15) described a series of 31 patients with AF
treated with thoracoscopic PV isolation and ganglionated
plexi ablation. In patients with nonparoxysmal AF, left
atrial ablation lines were created, and conduction block was
verified epicardially with custom-made catheters. After 1
year, they reported comparable results to ours (86% of
patients had no recurrence of SVT off AADs). Although
the autonomic nervous system seems to play an important
role in AF, there is until now too little evidence to advocate
a systematic ganglionated plexi ablation strategy (16,17). In
animal models, return of ganglionated plexi activity was
observed 4 weeks after selective ablation, and little is known
about the electrophysiological impact reinnervation will
have on long-term outcomes (18). An important conceptual
difference between studies is that Krul et al. (15) could only
perform epicardial lesions, without the possibility of adding
endocardial lesions including endocardial touch-ups to im-
prove transmurality, as well as performing CTI and left-
Holter
6 Months 9 Months 12 Months 24 Months
7 days, NSR 7 days, NSR 7 days, NSR —
7 days, NSR NA 7 days, NSR 7 days, NSR
7 days, NSR 7 days, NSR 7 days, NSR —
7 days, NSR — — —
7 days, NSR 7 days, NSR 7 days, NSR —
7 days, NSR 7 days, NSR 7 days, NSR —
7 days, NSR 7 days, NSR 7 days, NSR
7 days, NSR NA 7 days, NSR 7 days, NSR
7 days, NSR NA 7 days, NSR —
7 days, NSR 7 days, NSR 7 days, NSR —
7 days, NSR 7 days, NSR 7 days, NSR —
7 days, AFL 7 days, NSR 7 days, NSR —
48h, NSR 7 days, NSR 7 days, NSR —
7 days, NSR 7 days, NSR 7 days, NSR —
7 days, NSR 7 days, NSR 7 days, PAF —
7 days, NSR 7 days, NSR 7 days, NSR —
NA 7 days, NSR 7 days, NSR —
PM, NSR PM, NSR PM, NSR —
7 days, NSR 7 days, NSR 7 days, NSR —
7 days, NSR 7 days, NSR 7 days, NSR —
7 days, NSR NA 7 days, NSR —
7 days, NSR 7 days, NSR 7 days, NSR —
7 days, NSR NA 7 days, NSR 7 days, NSR
7 days, NSR — — —
7 days, NSR 7 days, NSR 7 days, NSR —
7 days, NSR NA 7 days, NSR —
cedure (AAD stop) is given for each patient. Patients 6, 12, 15, and 17 had arrhythmia recurrence.
able 1.MonitoringTable 2 Monitoring
Patient # AF Type
AAD Before
Procedure
AAD Stop
(months) 3 Months
1 Pers Sotalol 6 7 days, NSR
2 Pers Sotalol 6 48 h, NSR
3 Pers Amiodarone 6 24 h, NSR
4 Pers Flecainide Not stopped 24 h, NSR
5 Pers Amiodarone 6 7 days, NSR
6 Pers Flecainide 6 48 h, NSR
7 Pers Propafenone 6 7 days, NSR
8 Pers Disopyramide 6 7 days, NSR
9 Pers Metoprolol 6 48 h, NSR
10 Pers Amiodarone 6 7 days, NSR
11 Pers Amiodarone 6 7 days, NSR
12 Parox Flecainide 4 7 days, AFL
13 Parox Flecainide 6 48 h, NSR
14 Parox Sotalol 6 48 h, NSR
15 Parox Sotalol Not stopped 7 days, PAF
16 Parox Amiodarone 6 7 days, NSR
17 Parox Amiodarone 6 7 days, NSR
18 Parox Flecainide 3 PM, NSR
19 Parox Flecainide 6 48 h, NSR
20 Parox Flecainide 6 7 days, NSR
21 Parox Metoprolol 6 7 days, NSR
22 Parox Sotalol 6 7 days, NSR
23 Parox Flecainide 6 7 days, NSR
24 Parox Disopyramide 6 7 days, NSR
25 Parox Sotalol 6 7 days, NSR
26 Parox Flecainide 3 7 days, NSRFigure 5 Outcomes of Hybrid Ablation Procedures
Kaplan-Meier curve showing the outcomes of hybrid ablation procedures. At
1-year follow-up, hybrid ablation resulted in an overall single-procedure success
rate of 83% (79% for paroxysmal atrial fibrillation [AF] and 90% for persistent
AF). An event was considered a patient who, at any time after the blanking
period after the blanking period, had recurrent supraventricular tachycardia.sided isthmus ablation. In addition, they could check the
Sdia; oth
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which may be insufficient to show complete electrical block.
Study limitations. The small number of patients in this
single-center retrospective study prevents definitive conclu-
sions, also in view of the limited power of the log-rank test
we used to compare groups. However, future larger studies
may corroborate our results.
Although patients with previous CA had at most a PV
isolation procedure, and none of the PVs appeared to be
isolated in any of these patients, it cannot be excluded that
previous CA favorably influenced the results.
The single-procedure success rate was similar, rather than
lower, in patients with persistent compared with those with
paroxysmal AF. Although this may have been due to the
small sample size, it may also be considered an expression of
the robustness of the hybrid procedure.
In the present series, the overall clinical success may have not
recognized some episodes of asymptomatic arrhythmia by the
relatively short periods of ambulatory monitoring performed.
The safety of this procedure may be a concern because of
the extent of ablation and the full heparinization during the
procedure.
The longer-term impact of this ablation strategy on the
atrial systolic function remains unknown.
An ablation strategy based on noninducibility could lead
to overtreatment of some patients. As demonstrated by Jaïs
et al. (8), despite being still inducible after PV isolation and
deployment of linear lesions, some patients remained ar-
rhythmia free without AADs.
Conclusions
A combined transvenous endocardial and thoracoscopic
epicardial ablation procedure for paroxysmal and recent
persistent AF resistant to AADs has a single-procedure
success rate of 83% at 1 year. Recurrent arrhythmias can be
handled with AADs or CA.
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